OpenLB
Open Library of Bioscience
Advanced Search
International journal of molecular sciences
Dec 26, 2024;26 (1):

Targeting CD200 in Breast Cancer: Opportunities and Challenges in Immunotherapeutic Strategies.

Sihyang Baek, Kui Cui
Author Information
  1. Sihyang Baek: Western Reserve Academy, Hudson, OH 44236, USA.
  2. Kui Cui: Vascular Biology Program, Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. ORCID
PMID: 39795972 DOI: 10.3390/ijms26010115

Abstract

One of the key factors that contribute to tumor progression and resistance is the immunosuppressive microenvironment of the tumor. CD200 is a recently identified cell surface glycoprotein recognized as an important molecule in breast cancer for its versatile modulation of the immune response via its receptor, CD200R. The interaction between CD200 and CD200R suppresses the immune activities against tumor cells and allows them to be undetected and, in doing so, to escape from the destructive capability of the immune cells. Here, we review recent advances and future trends in CD200-targeted therapies for cancer treatments. We also discuss molecular pathways that include variable expressions across different cancer types and their importance in treatment options.

Keywords

CD200 CD200R breast cancer immune evasion

References

  1. Oncoimmunology. 2018 Feb 8;7(5):e1426517 [PMID: 29721394]
  2. Onco Targets Ther. 2016 Oct 11;9:6119-6125 [PMID: 27785059]
  3. Blood Adv. 2020 Nov 10;4(21):5402-5413 [PMID: 33147339]
  4. Expert Opin Investig Drugs. 2022 Sep;31(9):875-879 [PMID: 35920338]
  5. Tumour Biol. 2013 Feb;34(1):531-42 [PMID: 23179394]
  6. Drug Des Devel Ther. 2018 Feb 16;12:321-330 [PMID: 29497278]
  7. J Natl Cancer Inst. 2020 Jul 1;112(7):737-746 [PMID: 31665365]
  8. Cancer Res. 2017 May 1;77(9):2488-2499 [PMID: 28249908]
  9. J Immunother Cancer. 2019 Jul 23;7(1):193 [PMID: 31337439]
  10. Oncogene. 2012 Jun 14;31(24):2979-88 [PMID: 22020332]
  11. Trends Immunol. 2016 Jul;37(7):462-476 [PMID: 27216414]
  12. Front Pharmacol. 2020 Nov 16;11:580251 [PMID: 33364954]
  13. J Pathol. 2005 Jan;205(2):275-92 [PMID: 15641020]
  14. Biochem Biophys Res Commun. 2007 Dec 28;364(4):778-82 [PMID: 17964286]
  15. Drug Resist Updat. 2020 May;50:100683 [PMID: 32146422]
  16. Nat Med. 2020 Oct;26(10):1569-1575 [PMID: 33020647]
  17. Blood. 2006 Dec 15;108(13):4194-7 [PMID: 16946299]
  18. Cancer Treat Rev. 2018 Sep;69:152-163 [PMID: 30029203]
  19. Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):14-20 [PMID: 21907301]
  20. Neoplasia. 2016 Apr;18(4):229-41 [PMID: 27108386]
  21. J Clin Invest. 2021 Jan 4;131(1): [PMID: 32990678]
  22. Drug Resist Updat. 2020 Sep;52:100712 [PMID: 32599435]
  23. Cells. 2019 Apr 06;8(4): [PMID: 30959874]
  24. Sci Rep. 2017 Apr 21;7:46662 [PMID: 28429795]
  25. J Immunol. 2008 Jan 15;180(2):699-705 [PMID: 18178807]
  26. Head Neck. 2015 Mar;37(3):327-35 [PMID: 24700450]
  27. Nat Commun. 2015 Apr 29;6:6840 [PMID: 25924227]
  28. AAPS J. 2019 May 22;21(4):66 [PMID: 31119428]
  29. Oral Oncol. 2019 Jun;93:66-75 [PMID: 31109698]
  30. Nat Commun. 2019 Aug 23;10(1):3817 [PMID: 31444334]
  31. Small. 2020 Oct;16(43):e2004161 [PMID: 33000898]
  32. Front Immunol. 2020 Jul 14;11:1469 [PMID: 32760400]
  33. J Immunother Cancer. 2021 Dec;9(12): [PMID: 34873013]
  34. Oncotarget. 2015 Oct 6;6(30):30212-21 [PMID: 26338961]
  35. Oncotarget. 2023 Feb 04;14:96-103 [PMID: 36738455]
  36. Breast Cancer Res Treat. 2012 Nov;136(1):117-27 [PMID: 23053647]
  37. J Cancer. 2021 Jun 11;12(16):4841-4848 [PMID: 34234854]
  38. BMC Cancer. 2021 Aug 6;21(1):899 [PMID: 34362344]
  39. Front Cell Dev Biol. 2021 Oct 08;9:739816 [PMID: 34692697]
  40. Cancers (Basel). 2021 Oct 27;13(21): [PMID: 34771560]
  41. Clin Cancer Res. 2009 Dec 15;15(24):7479-7491 [PMID: 20008848]
  42. Breast Care (Basel). 2017 Oct;12(5):304-308 [PMID: 29234249]
  43. Oncotarget. 2015 Nov 10;6(35):37269-80 [PMID: 26452030]
  44. Oncol Lett. 2016 Oct;12(4):2271-2276 [PMID: 27698788]
  45. Eur J Cancer. 2016 Feb;54:139-148 [PMID: 26765102]
  46. J Theor Biol. 2013 Jul 7;328:65-76 [PMID: 23541619]
  47. Cancer Immunol Immunother. 2008 Jul;57(7):987-96 [PMID: 18060403]
  48. Int Immunol. 2005 Mar;17(3):289-96 [PMID: 15684038]
  49. Breast Cancer Res Treat. 2010 Sep;123(2):405-15 [PMID: 19953316]
  50. J Clin Invest. 2007 Dec;117(12):3922-9 [PMID: 18008004]
  51. Breast Care (Basel). 2017 Oct;12(5):290-294 [PMID: 29234247]
  52. Breast Cancer Res. 2019 May 17;21(1):65 [PMID: 31101122]
  53. Cancers (Basel). 2021 Aug 17;13(16): [PMID: 34439290]
  54. Transplantation. 2008 Oct 27;86(8):1116-24 [PMID: 18946351]
  55. J Clin Lab Anal. 2021 Nov;35(11):e24008 [PMID: 34545638]
  56. J Immunol. 2006 Jan 1;176(1):191-9 [PMID: 16365410]
  57. Cancers (Basel). 2021 Mar 01;13(5): [PMID: 33804482]
  58. Cell Rep. 2019 May 21;27(8):2411-2425.e9 [PMID: 31116985]
  59. Expert Opin Biol Ther. 2008 Jan;8(1):5-15 [PMID: 18081533]
  60. Nucleic Acids Res. 2010 Oct;38(19):6684-96 [PMID: 20558599]
  61. Cancer Immunol Immunother. 2011 Jul;60(7):931-42 [PMID: 21431419]
  62. NPJ Breast Cancer. 2021 Jul 16;7(1):94 [PMID: 34272387]
  63. Cancer Res. 2010 Apr 1;70(7):2962-72 [PMID: 20332223]
  64. Sci Rep. 2016 Oct 19;6:35383 [PMID: 27759034]
  65. Oncotarget. 2017 Jul 15;8(41):69756-69767 [PMID: 29050239]
  66. Endocr Relat Cancer. 2005 Mar;12(1):1-17 [PMID: 15788636]
  67. Breast Cancer Res Treat. 2020 Sep;183(2):419-428 [PMID: 32683565]
  68. Clin Pharmacol Ther. 2007 Mar;81(3):328-45 [PMID: 17339863]
  69. Ther Adv Med Oncol. 2021 Mar 10;13:1758835920987651 [PMID: 33796150]
  70. Cancer Immunol Res. 2018 Aug;6(8):930-940 [PMID: 30021725]
  71. Trends Cancer. 2020 Jul;6(7):580-592 [PMID: 32610068]
  72. Clin Cancer Res. 2003 Oct 15;9(13):4906-13 [PMID: 14581365]
  73. Neoplasia. 2018 Mar;20(3):263-279 [PMID: 29462756]
  74. PLoS One. 2016 Apr 25;11(4):e0152073 [PMID: 27111430]
  75. Leuk Res. 2017 Jul;58:31-38 [PMID: 28407515]
  76. Curr Drug Metab. 2007 Feb;8(2):109-36 [PMID: 17305491]
  77. J Clin Oncol. 1999 Jul;17(7):2180-9 [PMID: 10561274]
  78. Eur J Immunol. 2010 Sep;40(9):2569-79 [PMID: 20662098]
  79. Int J Mol Sci. 2019 Aug 25;20(17): [PMID: 31450712]
  80. Front Oncol. 2023 Jan 23;13:1088038 [PMID: 36756156]
  81. Biochem Biophys Res Commun. 2008 Feb 1;366(1):117-22 [PMID: 18060862]
  82. J Immunother Cancer. 2020 Jun;8(1): [PMID: 32581043]
  83. Lancet Oncol. 2016 Apr;17(4):425-439 [PMID: 26947331]
  84. BioDrugs. 2019 Apr;33(2):125-135 [PMID: 30847853]
  85. ACS Biomater Sci Eng. 2020 May 11;6(5):2563-2569 [PMID: 33463296]
  86. PLoS One. 2017 May 4;12(5):e0175128 [PMID: 28472085]
  87. Front Pharmacol. 2020 Jan 30;10:1671 [PMID: 32082164]
  88. Ann Oncol. 2017 Oct 01;28(10):2377-2385 [PMID: 28945858]
  89. Cell Biochem Funct. 2021 Oct;39(7):886-895 [PMID: 34235754]
  90. Oncologist. 2018 May;23(5):528-539 [PMID: 29352052]
  91. Cancers (Basel). 2019 Oct 17;11(10): [PMID: 31627350]
  92. Breast Cancer Res Treat. 2011 Nov;130(1):49-60 [PMID: 21165772]
  93. J Surg Res. 2008 Mar;145(1):87-96 [PMID: 17981299]
  94. J Immunother Cancer. 2014 Dec 16;2(1):46 [PMID: 25598973]
  95. Clin Cancer Res. 2020 Jan 1;26(1):232-241 [PMID: 31624103]
  96. Cancer Biother Radiopharm. 2000 Oct;15(5):495-505 [PMID: 11155821]
  97. Genes Dis. 2019 Jul 03;6(3):232-246 [PMID: 32042863]
  98. J Exp Clin Cancer Res. 2017 Dec 19;36(1):187 [PMID: 29258566]
  99. Adv Exp Med Biol. 2020;1223:155-165 [PMID: 32030689]
  100. Clin Cancer Res. 2022 Mar 1;28(5):821-830 [PMID: 34725098]
  101. Int J Mol Sci. 2021 Jul 27;22(15): [PMID: 34360781]
  102. Mol Pharm. 2020 Apr 6;17(4):1028-1048 [PMID: 32150417]
  103. Signal Transduct Target Ther. 2019 Dec 17;4:62 [PMID: 31871779]
  104. Leukemia. 2011 May;25(5):792-9 [PMID: 21274000]
  105. Neurotherapeutics. 2021 Jul;18(3):1980-1994 [PMID: 33829411]
  106. Med Sci Monit. 2016 Apr 01;22:1079-84 [PMID: 27035797]
  107. Drug Des Devel Ther. 2019 Jul 04;13:2215-2234 [PMID: 31308633]
  108. Curr Opin Immunol. 2012 Apr;24(2):233-8 [PMID: 22264927]
  109. BMC Cancer. 2014 Feb 04;14:59 [PMID: 24495356]
  110. Mol Ther Oncolytics. 2021 Sep 14;23:138-150 [PMID: 34703882]
  111. Cancer Res. 2017 Jul 1;77(13):3540-3550 [PMID: 28487385]
  112. Leuk Res. 2009 Mar;33(3):460-4 [PMID: 18838168]
  113. J Immunol. 2007 May 1;178(9):5595-605 [PMID: 17442942]
  114. Cancer Res. 2013 Mar 15;73(6):1733-41 [PMID: 23288508]
  115. Nat Rev Dis Primers. 2020 May 7;6(1):38 [PMID: 32382051]
  116. Front Oncol. 2019 Mar 13;9:138 [PMID: 30918839]
  117. Cells. 2020 Mar 20;9(3): [PMID: 32244924]
  118. PLoS One. 2012;7(2):e31442 [PMID: 22319630]
  119. Oncogene. 2015 Jul;34(29):3860-70 [PMID: 25263452]
  120. J Thorac Oncol. 2019 Aug;14(8):1378-1389 [PMID: 31026576]
  121. Int J Cancer. 2019 Sep 1;145(5):1179-1188 [PMID: 30478914]
  122. Ann Oncol. 2012 Dec;23(12):3007-3016 [PMID: 22865781]
  123. Cancers (Basel). 2020 Jul 03;12(7): [PMID: 32635224]
  124. Cancer Immunol Immunother. 2020 Nov;69(11):2333-2343 [PMID: 32514618]

MeSH Term

Humans
Breast Neoplasms
Female
Antigens, CD
Immunotherapy
Tumor Microenvironment
Molecular Targeted Therapy
Orexin Receptors
Animals

Chemicals

antigens, CD200
Antigens, CD
Orexin Receptors
CD200R1 protein, human
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0CD200cancerimmunetumorCD200RbreastcellsOnekeyfactorscontributeprogressionresistanceimmunosuppressivemicroenvironmentrecentlyidentifiedcellsurfaceglycoproteinrecognizedimportantmoleculeversatilemodulationresponseviareceptorinteractionsuppressesactivitiesallowsundetectedescapedestructivecapabilityreviewrecentadvancesfuturetrendsCD200-targetedtherapiestreatmentsalsodiscussmolecularpathwaysincludevariableexpressionsacrossdifferenttypesimportancetreatmentoptionsTargetingBreastCancer:OpportunitiesChallengesImmunotherapeuticStrategiesevasion

Similar Articles

Cited By

No available data.